- Home
- MBBC vs TPST Comparison
MBBC vs TPST Comparison
Compare MBBC & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBBC
- TPST
- Stock Information
- Founded
- MBBC 1902
- TPST 2011
- Country
- MBBC United States
- TPST United States
- Employees
- MBBC N/A
- TPST N/A
- Industry
- MBBC Banks
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- MBBC Finance
- TPST Health Care
- Exchange
- MBBC Nasdaq
- TPST Nasdaq
- Market Cap
- MBBC 29.3M
- TPST 33.0M
- IPO Year
- MBBC N/A
- TPST N/A
- Fundamental
- Price
- MBBC $10.10
- TPST $7.76
- Analyst Decision
- MBBC
- TPST Hold
- Analyst Count
- MBBC 0
- TPST 3
- Target Price
- MBBC N/A
- TPST $30.00
- AVG Volume (30 Days)
- MBBC 6.9K
- TPST 77.2K
- Earning Date
- MBBC 08-22-2025
- TPST 08-07-2025
- Dividend Yield
- MBBC N/A
- TPST N/A
- EPS Growth
- MBBC 103.56
- TPST N/A
- EPS
- MBBC 0.22
- TPST N/A
- Revenue
- MBBC $6,591,743.00
- TPST N/A
- Revenue This Year
- MBBC N/A
- TPST N/A
- Revenue Next Year
- MBBC N/A
- TPST N/A
- P/E Ratio
- MBBC $45.86
- TPST N/A
- Revenue Growth
- MBBC N/A
- TPST N/A
- 52 Week Low
- MBBC $6.38
- TPST $5.35
- 52 Week High
- MBBC $12.00
- TPST $28.34
- Technical
- Relative Strength Index (RSI)
- MBBC N/A
- TPST 63.65
- Support Level
- MBBC N/A
- TPST $6.11
- Resistance Level
- MBBC N/A
- TPST $6.49
- Average True Range (ATR)
- MBBC 0.00
- TPST 0.35
- MACD
- MBBC 0.00
- TPST 0.03
- Stochastic Oscillator
- MBBC 0.00
- TPST 100.00
About MBBC Marathon Bancorp Inc. Common Stock
Marathon Bancorp Inc is a Wisconsin-chartered savings bank. It is a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the Company's revenues come from interest income on loans and debt securities.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.